Kirchner H - Search Results

1

In vivo and ex vivo antitumor activity in patients receiving low-dose subcutaneous recombinant interleukin-2.

Schomburg A, Menzel T, Körfer A, Heer G, Dallmann I, Kirchner H, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: kirchner h. Nat Immun. 1992 May-Jun;11(3):133-43. Nat Immun. 1992. PMID: 1392401

2

Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.

Schomburg A, Kirchner H, Lopez-Hänninen E, Menzel T, Rudolph P, Körfer A, Fenner M, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: kirchner h. Am J Clin Oncol. 1994 Jun;17(3):199-209. doi: 10.1097/00000421-199406000-00004. Am J Clin Oncol. 1994. PMID: 7910716

3

Soluble interleukin 2 receptors abrogate IL-2 induced activation of peripheral mononuclear cells.

Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Zorn U, et al. Among authors: kirchner h. Cytokine. 1994 Jul;6(4):358-64. doi: 10.1016/1043-4666(94)90058-2. Cytokine. 1994. PMID: 7948742

4

Treatment of metastatic colorectal cancer patients with 5-fluorouracil in combination with recombinant subcutaneous human interleukin-2 and alpha-interferon.

Atzpodien J, Kirchner H, Hänninen EL, Menzel T, Deckert M, Franzke A, Schomburg A, Poliwoda H. Atzpodien J, et al. Among authors: kirchner h. Oncology. 1994 May-Jun;51(3):273-5. doi: 10.1159/000227348. Oncology. 1994. PMID: 8196911 Clinical Trial.

5

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.

Atzpodien J, Kirchner H, Hänninen EL, Deckert M, Fenner M, Poliwoda H. Atzpodien J, et al. Among authors: kirchner h. Eur J Cancer. 1993;29A Suppl 5:S6-8. doi: 10.1016/0959-8049(93)90617-o. Eur J Cancer. 1993. PMID: 8260264 Clinical Trial.

6

Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.

Atzpodien J, Kirchner H, Körfer A, Hadam M, Schomburg A, Menzel T, Deckert M, Franzke A, Volkenandt M, Dallmann I, et al. Atzpodien J, et al. Among authors: kirchner h. Tumour Biol. 1993;14(6):354-9. doi: 10.1159/000217850. Tumour Biol. 1993. PMID: 8265981

7

Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens.

Schomburg A, Kirchner H, Atzpodien J. Schomburg A, et al. Among authors: kirchner h. Acta Haematol. 1993;89(3):119-31. doi: 10.1159/000204503. Acta Haematol. 1993. PMID: 8362600 Clinical Trial.

8

Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy.

Schomburg A, Kirchner H, Atzpodien J. Schomburg A, et al. Among authors: kirchner h. J Cancer Res Clin Oncol. 1993;119(12):745-55. doi: 10.1007/BF01195347. J Cancer Res Clin Oncol. 1993. PMID: 8408187

9

Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.

Duensing S, Hadam M, Körfer A, Schomburg A, Menzel T, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Duensing S, et al. Among authors: kirchner h. Mol Biother. 1992 Dec;4(4):170-3. Mol Biother. 1992. PMID: 1282326

10

Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.

Schomburg A, Menzel T, Hadam M, Duensing S, Körfer A, Kirchner H, Poliwoda H, Atzpodien J. Schomburg A, et al. Among authors: kirchner h. Mol Biother. 1992 Jun;4(2):58-65. Mol Biother. 1992. PMID: 1515095

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

976 results

Search Page

Filters